research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
Search
for
Sort by
Research
30-60 / 1000+ results research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
research Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
research Prophylactic Amotosalen-Treated Donor T-Cells Prevent Late CMV Infection in Allogeneic Bone Marrow Transplantation.
Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research PROTACs: A novel strategy for cancer drug discovery and development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)
AH-001 could be a safer and more effective treatment for hair loss.
research Flammulina velutipes polysaccharide boosts the anti-tumor immunity by reversing M1/M2 polarization through TLR4/NF-κB activation
Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.
research Nemolizumab Treatment for Severe Atopic Dermatitis Led to the Simultaneous Improvement of Coexisting Refractory Alopecia Areata: A Case Report
Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research 032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses
The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
research Vemurafenib-induced pityriasis amiantacea: a case report
Vemurafenib can cause scalp issues but can be managed without changing the dose.
research Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
A pharmacovigilance study using the FDA Adverse Event Reporting System identified 1,389 cases of cutaneous adverse events (AEs) associated with enfortumab vedotin (EV), a treatment for urothelial carcinoma. Common AEs included rash, pruritus, and alopecia, with severe reactions like Stevens–Johnson syndrome. The study found 44 positive safety signals, 10 of which were previously unlabeled. Most AEs occurred within the first 2 weeks of treatment, primarily in elderly males. Concomitant prednisolone use increased AE reporting and mortality, while amlodipine use decreased AE reporting. These findings underscore the need for early dermatologic surveillance and personalized safety management during EV therapy.
research 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
research Bicalutamide
research Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression
Asparagus racemosus and Withania somnifera can help reduce side effects of a cancer drug.
research α‐Difluoromethylornithine, a polyamine inhibitor: its potential role in controlling hair growth and in cancer treatment and chemo‐prevention
DFMO may help control hair growth and treat cancer.
research Demethylation of ITGAV accelerates osteogenic differentiation in a blast-induced heterotopic ossification in vitro cell culture model
Removing a methyl group from the ITGAV gene speeds up bone formation in a specific type of bone disease model.
research Aminoacyl tRNA synthetase complex interacting multifunctional protein 1 induces proliferation of CD34+ hair follicle stem cell
AIMP1 can boost hair growth by increasing stem cell activity.
research AnnoPharma: Detection of substances responsible of ADR by annotating and extracting information from MEDLINE abstracts
AnnoPharma effectively identifies substances causing adverse drug reactions in medical abstracts.
research A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)
Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
research LB789 Novel IFNγ aptamer TAGX-0003 protected hair follicles from immune privilege collapse and reversed Alopecia Areata like phenotype in humanized mouse model
TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
research New drugs: Agalsidase alfa
Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
research EFFECTS OF α-MELANOCYTE-STIMULATING HORMONE AND [8-ARGININE]-VASOTOCIN UPON MELANOGENESIS IN HAIR FOLLICLE MELANOCYTES IN VITRO
α-MSH increases melanin production in moulting hair follicles, while AVT inhibits it.
research Immunopotentiator from Pantoea agglomerans 1 (IP-PA1) Promotes Murine Hair Growth and Human Dermal Papilla Cell Gene Expression.
IP-PA1 helps grow hair in mice and affects human cell growth-related genes differently than traditional hair growth treatments.